Formononetin is under investigation in clinical trial NCT02174666 (Isoflavone Treatment for Postmenopausal Osteopenia.).
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Prasterone | The risk or severity of adverse effects can be increased when Prasterone is combined with Formononetin. |
| Exemestane | The therapeutic efficacy of Exemestane can be decreased when used in combination with Formononetin. |
| Hyaluronidase (ovine) | The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Formononetin. |
| Hyaluronidase (human recombinant) | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Formononetin. |
| Hyaluronidase | The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Formononetin. |
| Lenalidomide | Formononetin may increase the thrombogenic activities of Lenalidomide. |
| Ospemifene | The risk or severity of adverse effects can be increased when Formononetin is combined with Ospemifene. |
| Ropinirole | Formononetin may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy. |
| Thalidomide | Formononetin may increase the thrombogenic activities of Thalidomide. |
| Cetuximab | Formononetin may increase the thrombogenic activities of Cetuximab. |
| Human immunoglobulin G | Formononetin may increase the thrombogenic activities of Human immunoglobulin G. |
| Omalizumab | Formononetin may increase the thrombogenic activities of Omalizumab. |
| Adalimumab | Formononetin may increase the thrombogenic activities of Adalimumab. |
| Gemtuzumab ozogamicin | Formononetin may increase the thrombogenic activities of Gemtuzumab ozogamicin. |
| Indium In-111 satumomab pendetide | Formononetin may increase the thrombogenic activities of Indium In-111 satumomab pendetide. |
| Infliximab | Formononetin may increase the thrombogenic activities of Infliximab. |
| Trastuzumab | Formononetin may increase the thrombogenic activities of Trastuzumab. |
| Rituximab | Formononetin may increase the thrombogenic activities of Rituximab. |
| Basiliximab | Formononetin may increase the thrombogenic activities of Basiliximab. |
| Muromonab | Formononetin may increase the thrombogenic activities of Muromonab. |
| Digoxin Immune Fab (Ovine) | Formononetin may increase the thrombogenic activities of Digoxin Immune Fab (Ovine). |
| Ibritumomab tiuxetan | Formononetin may increase the thrombogenic activities of Ibritumomab tiuxetan. |
| Tositumomab | Formononetin may increase the thrombogenic activities of Tositumomab. |
| Alemtuzumab | Formononetin may increase the thrombogenic activities of Alemtuzumab. |
| Capromab pendetide | Formononetin may increase the thrombogenic activities of Capromab pendetide. |
| Efalizumab | Formononetin may increase the thrombogenic activities of Efalizumab. |
| Antithymocyte immunoglobulin (rabbit) | Formononetin may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit). |
| Natalizumab | Formononetin may increase the thrombogenic activities of Natalizumab. |
| Palivizumab | Formononetin may increase the thrombogenic activities of Palivizumab. |
| Daclizumab | Formononetin may increase the thrombogenic activities of Daclizumab. |
| Bevacizumab | Formononetin may increase the thrombogenic activities of Bevacizumab. |
| Technetium Tc-99m arcitumomab | Formononetin may increase the thrombogenic activities of Technetium Tc-99m arcitumomab. |
| Eculizumab | Formononetin may increase the thrombogenic activities of Eculizumab. |
| Panitumumab | Formononetin may increase the thrombogenic activities of Panitumumab. |
| Ranibizumab | Formononetin may increase the thrombogenic activities of Ranibizumab. |
| Galiximab | Formononetin may increase the thrombogenic activities of Galiximab. |
| Pexelizumab | Formononetin may increase the thrombogenic activities of Pexelizumab. |
| Afelimomab | Formononetin may increase the thrombogenic activities of Afelimomab. |
| Epratuzumab | Formononetin may increase the thrombogenic activities of Epratuzumab. |
| Bectumomab | Formononetin may increase the thrombogenic activities of Bectumomab. |
| Oregovomab | Formononetin may increase the thrombogenic activities of Oregovomab. |
| IGN311 | Formononetin may increase the thrombogenic activities of IGN311. |
| Adecatumumab | Formononetin may increase the thrombogenic activities of Adecatumumab. |
| Labetuzumab | Formononetin may increase the thrombogenic activities of Labetuzumab. |
| Matuzumab | Formononetin may increase the thrombogenic activities of Matuzumab. |
| Fontolizumab | Formononetin may increase the thrombogenic activities of Fontolizumab. |
| Bavituximab | Formononetin may increase the thrombogenic activities of Bavituximab. |
| CR002 | Formononetin may increase the thrombogenic activities of CR002. |
| Rozrolimupab | Formononetin may increase the thrombogenic activities of Rozrolimupab. |
| Girentuximab | Formononetin may increase the thrombogenic activities of Girentuximab. |
| Obiltoxaximab | Formononetin may increase the thrombogenic activities of Obiltoxaximab. |
| XTL-001 | Formononetin may increase the thrombogenic activities of XTL-001. |
| NAV 1800 | Formononetin may increase the thrombogenic activities of NAV 1800. |
| Briakinumab | Formononetin may increase the thrombogenic activities of Briakinumab. |
| Otelixizumab | Formononetin may increase the thrombogenic activities of Otelixizumab. |
| AMG 108 | Formononetin may increase the thrombogenic activities of AMG 108. |
| Iratumumab | Formononetin may increase the thrombogenic activities of Iratumumab. |
| Enokizumab | Formononetin may increase the thrombogenic activities of Enokizumab. |
| Ramucirumab | Formononetin may increase the thrombogenic activities of Ramucirumab. |
| Farletuzumab | Formononetin may increase the thrombogenic activities of Farletuzumab. |
| Veltuzumab | Formononetin may increase the thrombogenic activities of Veltuzumab. |
| Ustekinumab | Formononetin may increase the thrombogenic activities of Ustekinumab. |
| Trastuzumab emtansine | Formononetin may increase the thrombogenic activities of Trastuzumab emtansine. |
| PRO-542 | Formononetin may increase the thrombogenic activities of PRO-542. |
| TNX-901 | Formononetin may increase the thrombogenic activities of TNX-901. |
| Inotuzumab ozogamicin | Formononetin may increase the thrombogenic activities of Inotuzumab ozogamicin. |
| RI 624 | Formononetin may increase the thrombogenic activities of RI 624. |
| Stamulumab | Formononetin may increase the thrombogenic activities of MYO-029. |
| CT-011 | Formononetin may increase the thrombogenic activities of CT-011. |
| Leronlimab | Formononetin may increase the thrombogenic activities of Leronlimab. |
| Glembatumumab vedotin | Formononetin may increase the thrombogenic activities of Glembatumumab vedotin. |
| Olaratumab | Formononetin may increase the thrombogenic activities of Olaratumab. |
| IPH 2101 | Formononetin may increase the thrombogenic activities of IPH 2101. |
| TB-402 | Formononetin may increase the thrombogenic activities of TB-402. |
| Caplacizumab | Formononetin may increase the thrombogenic activities of Caplacizumab. |
| IMC-1C11 | Formononetin may increase the thrombogenic activities of IMC-1C11. |
| Eldelumab | Formononetin may increase the thrombogenic activities of Eldelumab. |
| Lumiliximab | Formononetin may increase the thrombogenic activities of Lumiliximab. |
| Canakinumab | Formononetin may increase the thrombogenic activities of Canakinumab. |
| Ipilimumab | Formononetin may increase the thrombogenic activities of Ipilimumab. |
| Nimotuzumab | Formononetin may increase the thrombogenic activities of Nimotuzumab. |
| Clenoliximab | Formononetin may increase the thrombogenic activities of Clenoliximab. |
| Tocilizumab | Formononetin may increase the thrombogenic activities of Tocilizumab. |
| BIIB015 | Formononetin may increase the thrombogenic activities of BIIB015. |
| Sonepcizumab | Formononetin may increase the thrombogenic activities of Sonepcizumab. |
| Motavizumab | Formononetin may increase the thrombogenic activities of Motavizumab. |
| Elotuzumab | Formononetin may increase the thrombogenic activities of Elotuzumab. |
| AVE9633 | Formononetin may increase the thrombogenic activities of AVE9633. |
| Carotuximab | Formononetin may increase the thrombogenic activities of Carotuximab. |
| XmAb 2513 | Formononetin may increase the thrombogenic activities of XmAb 2513. |
| Coltuximab ravtansine | Formononetin may increase the thrombogenic activities of Coltuximab ravtansine. |
| Lucatumumab | Formononetin may increase the thrombogenic activities of Lucatumumab. |
| Pertuzumab | Formononetin may increase the thrombogenic activities of Pertuzumab. |
| Siplizumab | Formononetin may increase the thrombogenic activities of Siplizumab. |
| Apolizumab | Formononetin may increase the thrombogenic activities of Apolizumab. |
| Sibrotuzumab | Formononetin may increase the thrombogenic activities of Sibrotuzumab. |
| Bivatuzumab | Formononetin may increase the thrombogenic activities of Bivatuzumab. |
| Lerdelimumab | Formononetin may increase the thrombogenic activities of Lerdelimumab. |
| Lexatumumab | Formononetin may increase the thrombogenic activities of Lexatumumab. |
| Reslizumab | Formononetin may increase the thrombogenic activities of Reslizumab. |